Lenvatinib, another new oral, molecularly-targeted anti-cancer drug, possesses an anti-cancer effect in HCC by inhibiting multi-targeted tyrosine kinase inhibitors against VEGFR1-3, fibroblast growth factor receptor (FGFR)1-4, PDGFRα, RET and KIT 8. This evidence concerns the gene FGFR1 and hepatocellular carcinoma.